Daniel Chen, MD
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,910 of the $2,718 with a category attached, or 70.3%. 7 manufacturers reported payments, led by Livanova USA, Inc. at 47.9% of the total. Reporting peaked in 2019 at $1,384 and has fallen 96.5% since, to $49 in 2025.
Across 22 payments — averaging $123.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$1K
- Boston Scientific$1K
- Johnson & Johnson$113
- Novartis$25
- Acorda Therapeutics, Inc$23
- Amneal Pharmaceuticals LLC$20
- plus $13 from 1 others
What the payments were for
- Speaking & faculty fees$231%
- Travel & lodging$1,91070%
- Food & beverage$78529%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 5 | $1,303 |
| Boston Scientific | 8 | $1,222 |
| Johnson & Johnson | 5 | $113 |
| Novartis | 1 | $25 |
| Acorda Therapeutics, Inc | 1 | $23 |
| Amneal Pharmaceuticals LLC | 1 | $20 |
| Acadia Pharmaceuticals Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$1,206
- VERCISE$985
How this compares
$2,718 in reported general payments places this provider in the 75th percentile of 228 neurology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tetrabenazine | 14 | $135,100 |
| Aimovig AutoinjectorErenumab-Aooe | 53 | $86,557 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 1,075 | $47,064 |
| OnfiClobazam | 13 | $45,162 |
| Rasagiline Mesylate | 123 | $23,059 |
| UbrelvyUbrogepant | 16 | $15,821 |
| Selegiline Hcl | 135 | $15,256 |
| FycompaPerampanel | 11 | $12,854 |
| Primidone | 516 | $11,798 |
| Lacosamide | 77 | $10,615 |
| Ropinirole ErRopinirole Hcl | 111 | $10,142 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 169 | $9,048 |
| Levetiracetam | 218 | $8,339 |
| Divalproex Sodium ErDivalproex Sodium | 61 | $6,435 |
| Propranolol Hcl | 133 | $5,586 |
Paid to pharmacies, not to this prescriber.
Other neurology in Salem
- Keifong SeetoSalem$18K
- David ClarkSpringfield$1.1M
- Kyle SmootPortland$932K
- Chafic KaramPortland$727K
- Walter CarliniMedford$425K
- Herbert KrobPortland$416K
- Stanley CohanPortland$334K
- Matthew BrodskyPortland$123K
- Delaram SafarpourPortland$77K
- Kiren Kresa-ReahlPortland$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.